Introduction
Mast cells are tissue-resident immune cells that develop specialized morphologic and functional characteristics that allow them to contribute to site-specific immune responses [1, 2] . They possess numerous granules that contain preformed, proinflammatory mediators (histamine, heparin, chondroitin sulfate E, and serotonin), hydrolases (mast cell protease, tryptase, b-hexosaminidase), and lysosomal-like membrane proteins (LAMP-1, LAMP-2, and CD63). Granule contents are rapidly released when stimulated and, thereby, initiating an immune response (reviewed in Metcalfe et al. [3] ). During an immune response, mast cells are also capable of de novo synthesis of cytokines and other inflammatory mediators. Improper control of mast cell activation results in the aberrant release of inflammatory mediators, which contribute to many inflammatory diseases, most notably allergy and hypersensitivity disorders [4] .
Mast cells undergo degranulation, the release of granule contents extracellularly, in response to external stimuli by a process known as regulated exocytosis [5] . Mast cells express abundant levels of the high-affinity IgE receptor FceRI on their surface. Binding of multivalent Ags to FceRI-bound IgE induces receptor aggregation, triggering mast cell activation, which leads to granule mobilization and fusion at the plasma membrane [6, 7] . FceRI regulates degranulation by transmitting signals via intracellular ITAMs, which recruit and activate downstream signaling molecules, such as Src kinases and the leukocytespecific Syk. Syk phosphorylation of the adaptor protein LAT promotes the formation of a macromolecular complex that recruits PLCg, Vav1, SLP-76, and Btk [5] . Activation of PLCg generates IP 3 and diacylglycerol, which have a critical role in Ca 2+ mobilization and the activation of protein kinase C [8] [9] [10] . Vav1, a Rho GEF, activates Rho GTPases [11, 12] . The coordinated activation of these pathways provides a high level of regulation for mast cell degranulation.
Vav1 recruitment to the LAT complex in activated mast cells suggests that Rho signaling also has a role in inflammatory processes. Indeed, a role for multiple classes of Rho GTPases in degranulation has been established [9, [13] [14] [15] [16] [17] . As central regulators of actin-related morphologies, each member of the Rho GTPase family has a unique role in mediating actin remodeling. Using constitutively active and dominant-negative, mutant Rho proteins, previous research has defined important cytoskeleton rearrangements that occur in Ag-stimulated mast cells [16] [17] [18] . RhoA stimulates the formation of stress fibers, whereas Cdc42 and Rac stimulate the formation of branched F-actin structures present in filopodia and lamellipodia. Rac is involved in the formation of actin-rich dorsal membrane ruffles [19] , which we have shown to form in mast cells [13] . Mast cells undergo rapid morphologic changes upon stimulation, which is an integral part of transitioning to an activated state and may facilitate the degranulation mechanism. In this study, we examined the regulation of these processes by Rho proteins.
Previous research indicates that Rho proteins may be generally involved in exocytosis [20] and specifically involved in mast cell degranulation [9] . Here, we examined whether one or more Rho GTPase family members are critical for degranulation using the availability of new drugs that acutely inhibit their function. The Rac inhibitor EHT-1864 [21] , the Cdc42 inhibitor ML-141 [22] , the Rho inhibitor Rhosin [23] , the Rac1-Vav2 inhibitor EHop-016 [24] , and the TrioN/Tiam1-Rac1 inhibitor NSC-23766 [25] were all examined for their effect on mast cell activation and degranulation. Our studies show that Rac is the primary Rho GTPase involved in the regulation of mast cell morphologic transitions during activation, leading to degranulation. Drugs that target RhoA signaling also showed slight effects. Based on our results, we propose that Rho signaling would be an effective target for antiinflammatory therapy in disorders that involve mast cells.
MATERIALS AND METHODS

Cells and reagents
RBL-2H3 cells, obtained from ATCC (Manassas, VA, USA), were grown as monolayer cultures in MEM (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% heat-inactivated FBS (Thermo Fisher Scientific, Waltham, MA, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin (Thermo Fisher Scientific) at 37°C in a 5% CO 2 incubator. Cells were split every 2-3 d with 0.25% (wt/v) trypsin/1 mM EDTA (Thermo Fisher Scientific). BMMCs were derived by cytokine differentiation, as previously described [13] . Cells were sensitized by incubation with 120 ng/ml anti-DNP-IgE (clone SPE-7; SigmaAldrich) 4 h in MEM medium. For Ag-stimulation, sensitized cells were washed twice with HTB (25 mM HEPES, pH 7.4, 120 mM NaCl, 5 mM MgCl 2 , 1 mM CaCl 2 , 1 g/L glucose, and 1 g/L BSA), then stimulated by the addition of 27 ng/ml DNP-BSA (Thermo Fisher Scientific) for the times indicated. EHT-1864 (Rac inhibitor), ML-141 (Cdc42 inhibitor), Rhosin (RhoA inhibitor), NSC-23766 (Rac-Trio inhibitor), EHop-016 (Rac1-Vav2 inhibitor), and nocodazole (microtubule destabilizer) were purchased from Tocris Biosciences (Bio-Techne, Minneapolis, MN, USA); cytochalasin B (F-actin destabilizer) and HA-1100 (Rho-associated protein kinase (ROCK) inhibitor) were purchased from Sigma-Aldrich.
Immunoblotting
RBL-2H3 cells were plated in 6-well dishes and allowed to grow to confluency. Sensitized cells were washed twice with HTB and incubated with either DMSO or the indicated drugs for 30 min, followed by Ag stimulation. Cell lysates were prepared by adding 0.1 ml lysis buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-100, 0.1 mM PMSF, 10 mg/ml leupeptin, and 10 mg/ml pepstatin). Abs against phospho-Syk Y525/526 and total Syk (Cell Signaling Technology, Beverly, MA, USA) were used for immunoblot analysis.
Degranulation assay
The release of b-hexosaminidase from stimulated RBL-2H3 cells and BMMCs was used for degranulation assays [13, 14] . RBL-2H3 cells and BMMCs were plated in 24-well plates at a density of 2 3 10 5 cells/well and grown overnight.
Following sensitization, cells were washed twice with PBS and stimulated with varying concentrations of multivalent DNP-BSA in HTB to determine the ideal concentration of Ags. Degranulation assays were used to determine the effects of Rho drugs. Cells were plated and sensitized, then treated with different drugs or DMSO at varying concentrations for 30 min at 37°C. Cells were then washed in HTB and were Ag stimulated for 30 min. Levels of b-hexosaminidase secreted were determined, as previously described [26] . Briefly, 50 ml of extracellular supernatant was incubated with 50 ml of 1.2 mM MUG (Sigma-Aldrich) in 50 mM sodium citrate buffer (pH 4.5) for 30 min at 37°C; the reaction was terminated by the addition of 100 mM glycine (0.1 ml, pH 11). Cleavage of MUG by b-hexosaminidase releases the fluorescent product methylumbelliferone, which was detected with a Synergy-4 fluorometer set to em/ex of 360/460 nm (BioTek Instruments, Winooski, VT, USA). Fluorescence is directly proportional exocytosis, which was calculated as the percentage of b-hexosaminidase in the supernatant, divided by b-hexosaminidase from 0.5% Triton X-100-lysed cells (released/total). Data were analyzed by nonpaired, 2-tailed Student's t test to indicate a significant difference between 2 means 6 SEM.
Flow cytometry
Sensitized RBL-2H3 cells, harvested from an 80% confluent flask or 1 3 10 6 BMMCs were washed twice with HTB and preincubated with the indicated drugs at 40 mM for 30 min. Cells were then Ag-stimulated for 15 min and fixed with 4% (wt/v) paraformaldehyde for 30 min. Fixed cells were washed twice with annexin-binding buffer, and cells were stained with FITCannexin V (Sigma-Aldrich). For RBL-2H3 cells, a P4 gate was set for annexin V-negative cells, which included $95% of cells in the resting sample, and the P5 gate was set for annexin V-positive cells. For BMMCs, a P4 gate was set to include $95% of total cells, and cells outside the gate were quantified. The FACSDiva analysis program (BD Biosciences, Franklin Lakes, NJ, USA) was used to analyze data. Data were analyzed by nonpaired, 2-tailed Student's t test.
Rho activation assay
The levels of activated (GTP-bound) RhoA, Rac1, and Cdc42 were tested in resting and in Ag-stimulated cells by G-LISA assay, according to the manufacturer's protocol (Cytoskeleton, Denver, CO, USA). Briefly, RBL-2H3 cells were grown in 6-well plates at a density of 2 3 10 5 cells/well, or
BMMCs were plated at 1 3 10 6 cells/well. After sensitization, half of the wells were stimulated for 15 min, whereas the other half were left as resting controls. Cells were then lysed in the buffers provided, centrifuged to remove debris, and equivalent amounts of supernatant were incubated in 96-well microtiter dishes precoated with probes that specifically recognize the activated forms of RhoA, Rac1, and Cdc42. Constitutively active forms of Rho proteins (provided in the kit) were used as positive controls. After incubating for 30 min, wells were washed and incubated with primary Abs that recognize RhoA, Rac1, and Cdc42, followed by an HRP-conjugated secondary Ab. The levels of activated Rho proteins were determined by luminescence intensity of the HRP reagent using a Synergy-4 fluorometer (BioTek). Rho activation assays were also performed by pull-down assay, as previously described [27, 28] . Briefly, cell lysates were incubated with GST-CBD (which contains the Cdc42/Rac-binding domain from PAK1) or GST-RBD (which contains the Rho-binding domain from rhotekin) immobilized on 10 ml packed glutathione agarose (Sigma-Aldrich Live-cell, brightfield DIC and fluorescence microscopy was performed on RBL-2H3 cells to visualize cell morphology and granule dynamics during stimulation. Cells were plated and stained with LysoTracker green (Thermo Fisher Scientific) for granule-tracking experiments. Cells were imaged during Ag stimulation with a temperature-(37°C) and CO 2 (5%)-controlled, live-cell chamber to ensure ideal environmental conditions. Imaging was performed on a PerkinElmer (Waltham, MA, USA) Ultra-VIEW VoX spinning-disk, confocal microscope with a 363 objective (1.4 NA) and brightfield DIC with a 1-s exposure or brightfield and a 488 laser set to 10% power and 100 ms exposure. Images were taken every 10 s and processed with Velocity 6.0 software (Spirent Communications, Crawley, West Sussex, United Kingdom), which contained a particle-tracking module, and exported as .wmv (Windows media video) files at 10 frames/s.
RESULTS
Effect of Rho drugs on mast cell degranulation
Our goal here was to elucidate the role of Rho GTPases during regulated exocytosis in mast cells. For this study, we used the rat basophilic leukemia cell line, RBL-2H3, which has been a widely used model of mucosal mast cells and mouse BMMCs to study Fce-stimulated exocytosis [29] . RhoA, Rac1, and Cdc42 are the three main Rho proteins, and these were detected in RBL-2H3 and BMMCs lysates (Fig. 1A) ; Rac2, a hematopoietic-specific Rac isoform, was also detected, similar to previous results [9, 13] . To study the role of Rho GTPases, RBL-2H3 and BMMC activation and degranulation were assayed after treatment with commercially available Rho drugs. Syk, a hematopoietic kinase that transmits membrane-proximal activation signals from Fc receptors [30] , showed rapid activation via phosphorylation at Tyr 525/526 [31] (Fig. 1B) . None of the Rho drugs tested affected the levels of Syk phosphorylation (Fig. 1C) .
Degranulation was assayed by measuring the relative amount of b-hexosaminidase released from Ag-stimulated cells. BMMCs and RBL-2H3 cells showed a maximum of 53 and 37% exocytosis, respectively, when stimulated at 27 ng/ml of the Ag DNP-BSA (Fig. 1D ). The effect of acute inhibition of Rho GTPases was examined by preincubating cells with Rho drugs. Rhosin, ML-141, and EHT-1864 are direct inhibitors of RhoA, Cdc42, and Rac, respectively [21] [22] [23] ; in addition, the Rac-GEF-specific inhibitors NSC-23766 (TrioN and Tiam1) [25] and EHop-016 (Vav2) [24] and the Rho kinase inhibitor HA-1100 [32] were tested ( Fig. 1E and F) . EHT-1864 and Rhosin were the only drugs that reproducibly showed substantial inhibition of both RBL-2H3 cells and BMMCs. These results suggest that RhoA and Rac GTPases are involved in mast cell degranulation; however, drugs that target the Rho effector ROCK or the Rac GEFs TrioN, Tiam1, and Vav2 showed little to no effect.
Stimulated cells were also examined by flow cytometry. When mast cells are stimulated, the release of granular content results in the exposure of phosphatidylserine on the external surface of the cell, which can be quantified by FITC-annexin V staining [33, 34] . For RBL-2H3 cells, a P4 gate was set on resting cells that included 95% of cells and a P5 gate on stimulated cell that included 95% of cells not in P4 (Fig. 2A) . The percentage of cells that appeared in the P5-stimulated cell gate in each of the drug-treated samples was compared to the untreated, stimulated samples (Fig. 2B) . Stimulated RBL-2H3 cells showed a 12.1-fold increase in annexin V staining compared with resting cells when not pretreated with a drug. EHT-1864 was the only drug that caused a significant (74%) reduction in annexin V staining compared with untreated cells, which confirms that inhibition of Rac affects degranulation. EHop-016-treated RBL-2H3 cells also showed a slight, but statistically significant (29%), decrease in annexin V staining. The drugs ML-141, Rhosin, NSC-23766, and HA-1100 did not show a statistically significant effect. For BMMCs, cells outside the P4 gate were also quantified (Fig. 2C ). BMMCs treated with EHT-1864, Rhosin, and EHop-016 all showed a slight decrease in annexin V staining (Fig. 2D) , which confirms that inhibition of Rac, Rho, and possibly Vav2 affect degranulation in BMMCs. The drugs ML-141, Rhosin, NSC-23766, and HA-1100 did not show a statistically significant effect.
Rho activation during mast cell stimulation
To further examine the role of Rho proteins in mast cell stimulation and exocytosis, we performed a Rho protein activation assay. To determine which Rho proteins were activated by Ag stimulation, RBL-2H3 cells and BMMCs were lysed after 5 min of stimulation and the GTP-bound "on" state was affinity isolated with probes made from Rho-binding domains of downstream effectors [27, 28] . Rac1-GTP levels increased 2.6-and 1.9-fold in stimulated RBL-2H3 cells and BMMCs, respectively, compared with resting cells (Fig. 3A) . There was a slight increase in Cdc42-GTP levels in stimulated BMMCs cells but no change in RBL-2H3 cells, with high levels detected in both resting and stimulated cells (Fig. 3B) . The high basal Cdc42 activity in RBL-2H3 cells was likely due to those cells rapidly dividing, which requires Cdc42-GTP. RhoA-GTP levels increased 2.5-and 6.1-fold in stimulated RBL-2H3 and BMMCs, respectively, compared with resting cells; however, the overall levels were significantly lower compared with the standardized control (Fig. 3C) . In all cases, pretreatment of mast cells with Rho inhibitors blocked the activation of their cognate Rho protein when cells were stimulated (Fig. 3A-C, left bars) , which shows that the specific Rho inhibitors had the desired effect. These results indicate that Rac and Rho are activated for exocytosis in Ag-stimulated mast cells when combined with the observation that degranulation is reduced in EHT-1864-and Rhosin-treated cells.
Rho protein activation can be similarly assayed by affinity pull down with Rac and Rho activation probes, which we used to show their differential timing of activation (Fig. 3D ). Mast cells express both Rac1 and Rac2 [13] . To identify whether Rac activation is indicative of the activation of Rac1, Rac2, or both, lysates from stimulated RBL-2H3 cells were incubated with an immobilized Rac-activation probe, and the bound fraction was immunoblotted for Rac1 and Rac2 with specific Abs (Supplemental Fig. 1 ). Both Rac1-GTP and Rac2-GTP were detected 5 min after stimulation; EHT-1864 inhibited the generation of both Rac1-GTP and Rac2-GTP (Fig. 3E) . RhoA-GTP levels were detected after 20 min of stimulation and were inhibited by Rhosin (Fig. 3F) .
Dynamics of cytoskeletal remodeling during RBL-2H3 activation
Rho proteins control cell shape changes through regulation of cytoskeletal remodeling [19] . We imaged living cells by brightfield DIC microscopy and documented the morphologic transitions that occurred in RBL-2H3 cells during the FceR1 stimulation leading to degranulation. Still images from videos show the flattening of rounded cells within 10 min of stimulation (Fig. 4A , upper panels, and Supplemental Video 1). Cells first formed small surface ruffles, then larger surface ridges (Fig. 4A,  asterisk) , which culminated in large, peripheral protrusions and flattened cells (Fig. 4A, arrow) . These large protrusions were morphologically similar to CDRs observed in growth factorstimulated epithelial cells [35] [36] [37] [38] [39] . The formation of CDRs was dependent on Rac activation. EHT-1864, which effectively blocked degranulation (Fig. 1D) , also inhibited peripheral protrusion, cell flattening, and the formation of CDRs but did not inhibit minor surface ruffling or the formation of ridges (Fig.  4A and C, middle panels, and Supplemental Video 2). The development of surface ridges was dependent on Rho activation. Rhosin-treated cells formed surface ruffles but rarely formed ridges or CDRs (Fig. 4A and C, and Supplemental Video 3).
We further explored cytoskeletal changes by immunofluorescence microscopy. RBL-2H3 cells were fixed after 10 min of stimulation, and microtubules, F-actin, and granules were labeled with anti-b-tubulin Abs, Oregon green 488-phalloidin, and anti-CD63 Abs, respectively (Fig. 5A) . F-actin was enriched in surface ruffles and intensely stained peripheral projections of flattened cells (Fig. 5A, upper panels) . We also observed changes in the pattern of microtubule staining when cells were activated, which showed quite prominent track formation in peripheral projections. Whereas granules were randomly distributed in resting cells, they accumulated near the plasma membrane of peripheral protrusions (Fig. 5A) .
Stimulated RBL-2H3 cells pretreated with either EHT-1864 or Rhosin were similarly processed for immunofluorescence. In both cases, cell spreading was significantly reduced compared with untreated cells, peripheral projections did not form and F-actin showed punctate cytoplasmic staining (Fig. 5A , middle and lower panels). Granules remained dispersed throughout the cytosol. Microtubule tracks in the cell body remained in EHT-1864-treated cells (Fig. 5A , middle panels) but were noticeably absent in Rhosin-treated cells (Fig. 5A,lower panels) . Pretreatment with the ROCK inhibitor HA-1100 did not block peripheral projections or microtubule organization (Supplemental Figs. 2  and 3 ). These results suggest that cytoskeletal elements are uniquely controlled by Rho proteins during activation to drive the exocytosis process. Rac inhibition affected actin distribution in stimulated cells but did not affect microtubule patterns, whereas RhoA inhibition affected microtubule organization, which is mediated by a downstream effector that is unlikely to be ROCK (Supplemental Fig. 4 ). Both drugs reduced peripheral membrane spreading and the coincident distribution of granules to the cell periphery. This further defines the role of Rac and Rho in mast cell degranulation.
We also examined the effect of Rho drugs on primary mast cell F-actin and granule distribution by immunofluorescence microcopy (Fig. 5B ). BMMCs were stimulated for 10 min, fixed then F-actin, and granules were labeled with Oregon green 488 phalloidin and anti-CD63 Abs, respectively. F-actin was remodeled from a ring in resting cells to peripheral ruffling in stimulated cells, with a coincident increase in granule staining at the cell periphery (Fig. 5B, no drug) . The Rac and RhoA drugs EHT-1864 and Rhosin blocked the formation of this stimulated morphology, whereas the Cdc42 and ROCK drugs ML-141 and HA-1100 had little to no effect. These results confirm roles for Rac and RhoA in mast cell degranulation; RhoA works through a downstream effector complex that does not involve ROCK.
Rho-regulated granule motility
To examine the role of Rac and RhoA in the dynamics of granule movements, we looked at the effects of EHT-1864 and Rhosin treatment on RBL-2H3 cells stained with LysoTracker. LysoTracker has been used to stain both lysosomes and secretory granules in mast cells [40] . Two regions of interest were defined: the cell body, which contains larger, static lysosomes and smaller, motile granules; and the peripheral extensions, which contain mostly small, motile granules ( Fig. 6A and B) . LysoTrackerstained granules showed random movement in the cell body and nondirectional movement in peripheral cell extensions in resting cells (Fig. 6A , resting, and Supplemental Video 4). Upon stimulation, cell ruffles and peripheral extensions began to form (Fig. 6A , stimulated, and Supplemental Video 5), and granule motility slightly decreased in those regions by 17% (Fig. 6B) ; 10-15 min after stimulation, cells flattened, CDRs formed, and granules appeared to stream into flattened regions (Fig. 6A , poststimulation, and Supplemental Video 6). Rac-inhibited cells did not undergo flattening and did not form dorsal ruffles (Fig.  6A , middle panels-stimulated, and Supplemental Video 8). After 30 min poststimulation, some cell flattening was observed, but granules were static and accumulated at the cell body-peripheral extension boundaries (Fig. 6A middle panels-poststimulation, and Supplemental Video 9). The Rac inhibitor EHT-1864 reduced granule motility in the cell periphery, both before and during stimulation, by ;64% compared with untreated cells (Fig.  6B) . RhoA-inhibited cells showed increased granule motility, both before and during stimulation, by ;74% compared with untreated cells (Fig. 6B) . RBL-2H3 cells treated with Rhosin did not have a robust response upon stimulation (Fig. 6A , bottom panelsstimulated, and Supplemental Video 11), and after long periods of stimulation, cells spread slightly (Fig. 6A , poststimulation, and Supplemental Video 12) but did not flatten and polarize as observed in untreated cells. These results suggest that Rac may instigate cytoskeletal remodeling and flattening in the cell peripheral regions, whereas RhoA may facilitate granule capture and directional motility for exocytosis. This may facilitate granule exocytosis by controlling motility in peripheral ruffles that are in the active zone to increase fusion stochastically.
Effect of drugs targeting cytoskeleton
Mast cell stimulation results in activation of Rho GTPases, which recruit a variety of effector complexes that include many cytoskeletal remodeling proteins [41] . Rac1 effectors regulate the local assembly/disassembly of F-actin, which promotes lamellipodia formation, as observed during RBL-2H3 cell spreading (reviewed in Sit et al. [41] ). Studies have implicated Rho signaling in the regulation of microtubule dynamics [42] [43] [44] , whereas Nishida et al. [45] and Ogawa et al. [46] also demonstrated that microtubule remodeling stimulated by FceRI signaling is required for mast cell degranulation. Hence, we decided to examine the effect of targeting the cytoskeleton of RBL-2H3 cells with drugs that destabilize actin (cytochalasin B) and microtubules (nocodazole). Consistent with previous research in mast cells [45, 47] , we observed cytochalasin B, which disrupts F-actin assembly, led to a 33.4% increase in degranulation (Fig. 7A) . These results are consistent with the idea that disassembly of cortical F-actin is required for granule fusion to the plasma membrane. When we disrupted microtubule formation and stability using nocodazole, we observed a 54% decrease in response to Ag stimulation via the degranulation assay (Fig. 7A) .
To further define the role of the cytoskeleton in the dynamics of granule movements, we examined LysoTracker-stained RBL-2H3 cells treated with cytochalasin B and nocodazole to depolymerize F-actin and microtubules. LysoTracker-stained granules showed increased motility when actin was depolymerized ( Fig. 7B and C and Supplemental Video 14) and arrested motility when microtubules were depolymerized ( Fig. 7B and C; and Supplemental Video 15). In addition, nocodazole-treated cells caused a slow retraction of peripheral cell protrusions and accumulated granules in the cell body. These data support the idea that actin remodeling drives cell shape changes (i.e., flattening and ruffling) that facilitate granule exocytosis, whereas microtubules facilitate granule movement into the cell periphery, which are the active zones for degranulation (see model in Fig. 8 ). 
DISCUSSION
Aberrant mast cell degranulation has been implicated in a number of inflammatory disorders [4, 48, 49] . Our goal here was to further understand the cellular regulation of FceRI-mediated degranulation in mast cells, with a focus on pharmacologic intervention. Previous research implicated RhoA [16] , Cdc42, and/or Rac [9, 14, 16, 50] in degranulation of secretory vesicles in RBL-2H3 cells, largely through genetic manipulation of their expression. Field et al. [50] used mutant RBL cell lines to demonstrate that activation of Rho GTPases was critical for degranulation. However, the use of genetic perturbation can confound results if cell adaptation occurs during growth and passage. Therefore, we took the approach to acutely inhibit Rho proteins with drugs and to examine the effect within a few minutes of application, minimizing long-term effects.
Pharmacologic approaches that acutely inhibit target proteins are often advantageous over genetic methods, which are clearly not feasible for studies that involve essential genes. However, that approach is restricted to proteins that have small molecule, membrane-permeable inhibitors. In addition, the potential of off-target effects must be considered. In cases in which the target belongs to a protein family, assays to show selectivity are necessary to assess preferential activity for the desired target. Numerous, new, small molecule compounds that inhibit Rho GTPase have been identified recently, largely through functiondirected screens of compound libraries [21, 22] or in silico docking [23, 25] . We used those compounds as "Rho drugs" to acutely inhibit the Rho protein function and to characterize events leading to degranulation. We showed selectivity of those compounds with Rho-activation assays (Fig. 3) . All Rho GTPases Granule motility in the cell body and cell periphery was quantified before and after stimulation (left and right panels, respectively). Changes in granule velocities were compared between stimulation and resting conditions. EHT-1864-treated cells showed a significant decrease in the motility of granules in the cell periphery, whereas Rhosintreated cells showed an increase in granule motility. NS, not significant; **P , 0.01; ***P , 0.001; n $ 6 cells, with a minimum of 10 granules tracked in each region of interest.
examined showed increased levels of activation in extracts of stimulated mast cells. However, Rac-GTP levels showed the most significant increase, with rapid activation kinetics. RhoA-GTP levels also increased but with a much smaller yield and slower activation kinetics compared with Rac ( Fig. 3A and C ). This correlates with the effect of drugs. The Rac inhibitor EHT-1864 showed the greatest inhibition of mast cell degranulation, significant reduction in the exocytosis of granule enzymes (Figs. 1E and F and 2), and blocked morphologic transitions in stimulated cells (Fig. 4A) , resulting in granule accumulation in the cell body (Figs. 5 and 6 ). The RhoA inhibitor Rhosin also inhibited degranulation, although to a lesser degree than EHT-1864 (Figs. 1E and F and 2). Rhosin inhibited morphologic transitions differently than EHT-1864 did; cells still flattened, and granules were mobilized into the flattened cell periphery (Figures 4 and 6) . These results suggest that Rac and RhoA have distinct roles in regulating mast cell degranulation (Fig. 8) .
Two additional Rac drugs were tested that affect specific Rac-GEF interactions. NSC-23766, which blocks the interaction with TrioN and Tiam1, had no significant effect on degranulation; however, EHop-016, which blocks the Vav2-Rac1 interaction, inhibited at high micromolar concentrations. Because EHop-016 reportedly inhibits Vav2 binding at low micromolar concentration (IC 50 ; 1 mM) [24] , it may be an off-target effect. There are three structurally related Vav GEFs, and it may be that another member is required. Vav1 is recruited to LAT, a nucleating site for multiprotein signaling complexes in leukocytes [51] . Vav1-deficient bone marrow mast cells also exhibited reduced degranulation [52] . Vav1 activates RhoA, Rac, and Cdc42, which makes it an intriguing possibility as a central upstream factor that may control the downstream activation of several Rho proteins. The ROCK inhibitor HA-1100 was also examined but did not show any major effects. Therefore, RhoA must use a different effector to activate mast cell degranulation, and previously, formins have also been shown to have a role in cytoskeletal reorganization during stimulation [53] . We interpret the role of Rho proteins as the rapid activation of Rac1 to trigger cell flattening, projecting granules into lamellipodia for degranulation, and subsequent activation of RhoA to halt granules in active exocytosis zones (Supplemental Videos 4-12). Studies into temporal control of Rho GEF signaling are needed to elucidate the coordination of this mechanism.
Rho proteins have a role in cytoskeletal dynamics that invoke cell movement and shape changes. Rac activation regulates actin dynamics that give rise to the formation of lamellae and cell spreading on the substratum. Research in neutrophils has demonstrated a role for Rac GTPases in the regulation of exocytosis in conjunction with actin remodeling [54] [55] [56] . The question is whether those events are linked, so that morphologic transitions drive degranulation, or whether Rac and Rho drive two independent events. When stimulated, RBL-2H3 mast cells underwent a series of ordered morphologic transitions that occurred in conjunction with degranulation. Cells rapidly flattened and displayed small, surface ruffles and, after longer periods of stimulation, formed major, surface ruffles (Fig. 4 and Supplemental Video 1). These large membrane surface protrusions were morphologically similar to CDRs observed in growth factorstimulated epithelial cells [35] [36] [37] [38] [39] . In epithelial cells, the function of CDRs is proposed to be rapid internalization of integrins, which redistribute to newly forming focal adhesions at the leading edge to facilitate cell migration. In mast cells, CDRs may be similar to structures that take part in pinocytosis, which is deemed important for the removal of cortical actin and the reduction of an actin barrier to degranulation [57] . The formation of CDRs was dependent on Rac activation and coincided with the timing of peak degranulation. We did not observe the trafficking of granules into CDRs; however, because they formed above the focal plane in confocal mode, they may have eluded their detection. Thus, it remains possible that CDRs generate sites of exocytosis.
Peripheral extensions seem to be where degranulation takes place in RBL-2H3 cells. Granule motility in peripheral extensions was significantly greater and, in conjunction with cell flattening, could facilitate granule docking and exocytosis at the plasma membrane. We used drugs that destabilize actin and microtubule polymers to interfere with cytoskeletal dynamics and examined the ability of mast cells to respond to stimuli. We observed that targeting F-actin with cytochalasin resulted in increased degranulation, even though actin-driven morphologic changes were absent (Fig. 7 and Supplemental Video 14) . The increase in degranulation may be the result of the depolymerization of cortical actin, which has been deemed a barrier to exocytosis, and the increase in granule motility we observed, which could increase docking events stochastically at the plasma membrane [58] . Granule motility in peripheral regions was significantly slowed by the Rac inhibitor EHT-1864 and the microtubule destabilizing drug nocodazole (Supplemental Videos 8 and 15); both of which also inhibited degranulation (Figs. 1E and F and 7A). Nocodazole caused retraction of peripheral extension, which likely resulted in the inability to generate competent degranulation sites. Examination of cytoskeletal drugs clearly demonstrated the need for actin-driven morphologic changes (e.g., cell flattening), which may facilitate the fusion of granules to the plasma membrane. Simultaneously, microtubule extensions may facilitate granule movement into the cell periphery, which are active zones for degranulation. In conclusion, through the use of Rho inhibitors, we found that Rho signaling through Rac controls mast cell morphology, which transitions to an activated state to facilitate degranulation. RhoA may also participate in the morphology and granule movement during degranulation.
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